GLPG 2737Alternative Names: GLPG-2737
Latest Information Update: 30 Nov 2016
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cystic fibrosis